Key Takeaways Cencora shares rose 13.4% in six months as its U.S. Healthcare Solutions business supports growth.Cencora benefits from strong specialty drug demand in oncology and retina, backed by MSO investments.Cencora faces headwinds from international weakness, slower GLP-1 growth, and the loss of a grocery customer.Cencora, Inc. (COR) is well-poised for growth on the back of a robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern.Shares of this Zacks ...